Single B cell platforms have emerged as powerful tools for antibody discovery, enabling the rapid isolation and screening of thousands of antigen-specific B cells while preserving the native heavy and light-chain pairing critical to antibody function and selectivity. Among current variants, FACS-guided single B-cell sorting offers strong precision and throughput, making it an attractive option for programs where both speed and selectivity matter. This webinar explores how workflow selection after sorting can help reduce delays and improve efficiency in antibody discovery programs.
Once antigen-specific B cells have been sorted, researchers face a practical workflow decision: proceed through B cell culture to recover natively expressed antibodies or move directly to recombinant antibody expression using molecular biology techniques. Both approaches are well-established, but they are not interchangeable. Understanding which one aligns with the program’s goals and timeline from the outset can meaningfully reduce time spent on steps that may not be necessary for a specific application.
In this webinar, the featured speaker will explore case studies comparing these two single B-cell post-sort workflows side by side. Drawing on hands-on experience deploying both approaches, the presentation will outline the practical considerations that should inform workflow selection: desired throughput, timeline, sequence recovery rate and the tradeoffs between culture-based and direct expression strategies.
By the end of the session, attendees will have a clearer framework for selecting the most appropriate post-FACS strategy for their antibody discovery programs. Whether working in early discovery, translational research or platform development, this webinar will provide actionable guidance to optimize single B-cell workflows for improved efficiency and success.
Register for this webinar to learn how to choose the right post-FACS single B cell workflow for Antibody Discovery.
Speaker
Alain Agnememel, PhD, Principal Scientist, Antibody Discovery, Rockland Immunochemicals
Dr. Alain Agnememel is an Immunologist specializing in antibody discovery, vaccine development and diagnostic assay design. At Rockland, he leads recombinant antibody development, including yeast and phage display, overseeing the generation of naïve and immune libraries from multiple species and advancing single B-cell workflows to deliver high‑quality recombinant antibodies for research, diagnostics and therapeutic discovery.
Alain brings a strong foundation in immunology to his platform development work at Rockland. His academic and research training spans institutions in Switzerland, France, Canada and the United States, where he developed deep expertise in vaccinology, diagnostic test development, immunogenicity, antigenicity and antibody response characterization. His background in understanding how antibodies are generated and selected informs his current work designing and deploying discovery platforms that isolate and recover high-quality antigen-specific candidates.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Antibody Discovery Scientists working with hybridoma, single B-cell or display-based platforms
- Immunologists and Research Scientists in academic or industry settings focused on therapeutic, diagnostic or research antibody development
- Protein Scientists and Biochemists involved in recombinant antibody expression and characterization
- R&D Leaders and Principal Investigators evaluating or scaling single B cell workflows for their programs
- Biotech and Pharma Researchers in early-stage discovery, particularly those working on oncology, infectious disease or rare antigen targets
What You Will Learn
Attendees will gain insight into:
- How FACS-guided single B-cell sorting preserves native heavy/light chain pairing and enables high-throughput antigen-specific screening
- The functional differences between B-cell culture-based and recombinant antibody expression-based post-sort workflows and what each approach is optimized for
- A practical decision framework for selecting the right workflow based on discovery goals and timeline
- Real-world case study data comparing hit rates and timelines across both approaches
Xtalks Partner
Rockland
Established in 1962, Rockland Immunochemicals, Inc. is a privately held biotechnology company specializing in antibody and protein production near Philadelphia, Pennsylvania. As a trusted partner to the global life science community, Rockland supports academic, diagnostic, and biopharma research with high-quality, validated antibody-based tools. Our products are designed to advance discovery and ensure confidence in complex applications.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account